Definium Therapeutics (DFTX) Non-Current Deferred Tax Liability (2020 - 2021)
Definium Therapeutics (DFTX) reported Non-Current Deferred Tax Liability of $6.8 million for Q3 2021, little changed on a QoQ basis from $6.8 million in Q2 2021.
Definium Therapeutics (DFTX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $6.8 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 6.75 Mn |
| Sep 30, 2021 | 6.75 Mn |
| Jun 30, 2021 | 6.75 Mn |
| Jun 30, 2021 | 6.75 Mn |
| Mar 31, 2020 | 6.75 Mn |
| Mar 31, 2020 | 6.75 Mn |